RESUMO
Picrorhiza kurroa (Pk), a known hepatoprotective plant, was studied in experimental and clinical situtations. The standardization of active principles--Picroside 1 and 2 was done with High Performance Liquid Chromatography. Picroside 1 ranged from 2.72 to 2.88 mg/capsule and picroside 2 from 5.50 to 6.00 mg/capsule. In the galactosamine-induced liver injury in rats, Pk at a dose of 200 mg/kg p.o. showed a significant reduction (p < 0.05) in liver lipid content, GOT and GPT. In a randomised, double-blind placebo controlled trial in patients diagnosed to have acute viral hepatitis (HBsAg negative), Pk root powder 375 mg three times a day was given for 2 weeks (n = 15) or a matching placebo (n = 18) was given. Difference in values of bilirubin, SGOT and SGPT was significant between placebo and Pk groups. The time in days required for total serum bilirubin to drop to average value of 2.5 mg% was 75.9 days in placebo as against 27.44 days in Pk group. The present study has shown a biological plausability of efficacy of Pk as supported by clinical trial in viral hepatitis, hepatoprotection in animal model and an approach for standardizing extracts based on picroside content.
Assuntos
Doença Aguda , Alanina Transaminase/sangue , Animais , Aspartato Aminotransferases/sangue , Bilirrubina/sangue , Cinamatos/química , Modelos Animais de Doenças , Método Duplo-Cego , Avaliação Pré-Clínica de Medicamentos , Glicosídeos/química , Hepatite Viral Humana/tratamento farmacológico , Humanos , Hepatopatias/tratamento farmacológico , Masculino , Ayurveda , Distribuição Aleatória , Ratos , Ácido Vanílico/químicaRESUMO
An open comparative trial was conducted in 58 adult obese patients (Body Mass Index > or = 25 kg/square metre). Group I (n = 27), non-drug, was advised diet (1200-1600 cals) and a brisk walk for 30 minutes. Group II, in addition, received Guggulu (Medohar) 1.5-3 gms/day for 30 days. Mean difference in weight loss between Guggulu and non-drug group was 0.32 kg (ns) on day 15 and 0.58 kg on day 30 (ns). The mean weight reduction in patients (> 90 kgs) was 1.92 kg (ns) and 2.25 kg (ns) higher in Guggulu group. All patients weighing > 90 kg lost weight in Guggulu group whilst 3 in non-drug group did not lose weight. Guggulu was tolerated well. The data from this pilot study suggest a synergistic diet-Guggulu interaction over 30 days in patients weighing > 90 kgs which needs to be confirmed in a large placebo controlled study.
Assuntos
Adulto , Feminino , Humanos , Masculino , Ayurveda , Pessoa de Meia-Idade , Obesidade/tratamento farmacológico , Projetos Piloto , Extratos Vegetais/uso terapêutico , Plantas Medicinais , Estatísticas não Paramétricas , Resultado do TratamentoRESUMO
BACKGROUND: There have been conflicting data in literature about the value of Phyllanthus amarus in treating hepatitis B virus-related disorders. AIM: To evaluate the role of Phyllanthus amarus in eradication of the virus in hepatitis B carriers. METHODS: Phyllanthus amarus was administered to 30 asymptomatic carriers of hepatitis B surface antigen (HBsAg) in a dosage of 250 to 500 mg thrice daily for 4 to 8 weeks. RESULTS: None of the 30 subjects cleared HBsAg. Phyllanthus amarus was well tolerated, with no clinical side effects or changes in the organ profiles for safety evaluation. CONCLUSION: Phyllanthus amarus is not effective in clearing HBsAg in asymptomatic carriers of the antigen.